Classes
Publications
- The Inclusion of a Gemcitabine + Nab-paclitaxel Regimen as a 2nd Line Treatment for Advanced Pancreatic Cancer - First Experience2017 | First Faculty of Medicine, Faculty of Physical Education and Sport
- The Inclusion of a Gemcitabine Nab-paclitaxel Regimen as a 2nd Line Treatment for Advanced Pancreatic Cancer - First Experience2017 | First Faculty of Medicine, Faculty of Physical Education and Sport
- The Inclusion of a Gemcitabine + Nab-paclitaxel Regimen as a 2nd Line Treatment for Advanced Pancreatic Cancer - First Experience2017 | First Faculty of Medicine
- Therapeutic algorithm for pancreatic cancer - can we expect improved survival in near future?2016 | First Faculty of Medicine
- PALB2 as Another Candidate Gene for Genetic Testing in Patients with Hereditary Breast Cancer in Czech Republic2016 | First Faculty of Medicine
- The c.657de15 variant in the NBN gene predisposes to pancreatic cancer2016 | First Faculty of Medicine
- Modified FOLFIRINOX in the treatment of pancreatic cancer - efficiency and toxicity2016 | First Faculty of Medicine
- Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic2016 | First Faculty of Medicine
- Inclusion of the FOLFIRINOX regimen in the treatment algorithm for metastatic pancreatic cancer - First experience2014 | First Faculty of Medicine
- Human Pancreatic Cancer PanelPublication without faculty affiliation
Loading network view...